삼성서울병원

Ko En

혈액종양내과 박세훈 교수

진료분야
폐암, 두경부암, 식도암, 흉선암
진료일정 06 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
오전
오후
진료일정 07 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후

학력

학력
2020.09 성균관대학교 의과대학 박사학위 취득
2016.02 서울대학교 의과대학 석사학위 취득
2009.02 서울대학교 의과대학 졸업

경력

경력
2022.03 ~현재 삼성서울병원 혈액종양내과 조교수
2019.12 ~ 2022.02 삼성서울병원 혈액종양내과 임상조교수
2017.12 ~ 2019.11 삼성서울병원 혈액종양내과 임상강사
2016.06 ~ 2017.11 Roche/Genentech
2012.03 ~ 2016.02 서울대학교병원 내과 레지던트 수료
2011.03 ~ 2012.02 서울대학교병원 인턴 수료

학회활동

학회활동
대한내과학회 회원
대한암학회 회원
대한폐암학회 회원
미국암연구학회(AACR) 회원
미국임상암학회(ASCO) 회원
세계폐암학회(IASLC) 회원

수상이력

수상이력
2023.12 함춘내과 젊은의학자상
2023.11 분쉬의학상 젊은의학자상
2023.05 대한종양내과학회 폐암학술상
2021.11 보건의료기술진흥 유공자 정부포상 장관표창
  • J IMMUNOTHER CANCER 2024 10.1136/jitc-2023-008339 Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types Shen, JN; Choi, YL; Lee, T; Kim, H; Chae, YK; Dulken, B; Bogdan, S; Huang, M; Fisher, GA; Park, S; Lee, SH; Hwang, JE; Chung, JH; Kim, L; Song, H; Pereira, S; Shin, S; Lim, Y; Ahn, CH; Kim, S; Oum, C; Kim, S; Park, G; Song, S; Jung, W; Kim, S; Bang, YJ; Mok, TSK; Ali, SM; Ock, CY
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.461 First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • CANCER-AM CANCER SOC 2024 10.1002/cncr.35175 Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
    View PubMed
  • HISTOPATHOLOGY 2024 10.1111/his.15146 PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system Hwang, S; Hong, TH; Kim, HK; Cho, J; Lee, G; Choi, S; Park, S; Lee, SH; Lee, Y; Jeon, YJ; Lee, J; Park, SY; Cho, JH; Choi, YS; Kim, J; Zo, JI; Shim, YM; Choi, YL
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643 Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
    View PubMed
  • ESMO OPEN 2023 10.1016/j.esmoop.2023.102068 Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCERS 2023 10.3390/cancers15225450 Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
    View PubMed
  • J CACHEXIA SARCOPENI 2023 10.1002/jcsm.13345 Prognostic significance of body mass index in small-cell lung cancer: Exploring the relationship with skeletal muscle status Kwon, YJ; Yoon, YC; Kim, HS; Cha, MJ; Park, S; Lee, JH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.403 Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.35059 Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.502 Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027 Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160 Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • ESMO OPEN 2023 10.1016/j.esmoop.2023.101586 Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group Loong, HH; Shimizu, T; Prawira, A; Tan, AC; Tran, B; Day, D; Tan, DSP; Ting, FIL; Chiu, JW; Hui, M; Wilson, MK; Prasongsook, N; Koyama, T; Reungwetwattana, T; Tan, TJ; Heong, V; Voon, PJ; Park, S; Tan, IB; Chan, SL; Tan, DSW
    View PubMed
  • SUPPORT CARE CANCER 2023 10.1007/s00520-023-07779-3 Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial Lee, M; Kang, D; Kang, E; Kim, S; Kim, Y; Ahn, JS; Park, S; Lee, YY; Oh, D; Noh, JM; Cho, JH
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.34892 A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.910 Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma Lee, MS; An, S; Song, JY; Sung, M; Jung, K; Chang, ES; Choi, J; Oh, DY; Jeon, YK; Yang, H; Lakshmi, C; Park, S; Han, J; Lee, SH; Choi, YL
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1344 The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.388 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • MODERN PATHOL 2023 10.1016/j.modpat.2023.100184 Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-006454 High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis Jung, JY; Heo, YJ; Park, S
    View PubMed
  • ADV SCI 2023 10.1002/advs.202204378 Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
    View PubMed
  • HISTOPATHOLOGY 2023 10.1111/his.14894 Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma Hong, TH; Hwang, S; Choi, YL; Lee, GEH; Park, S; Ahn, MJ; Lee, Y; Jeon, YJ; Lee, J; Shin, S; Park, SY; Cho, JH; Choi, YS; Kim, J; Shim, YM; Cho, JH; Kim, HK
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509 Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1603 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018 Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.5460 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879 Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
    View PubMed
  • ISCIENCE 2022 10.1016/j.isci.2022.105358 Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
    View PubMed
  • PLOS ONE 2022 10.1371/journal.pone.0274830 Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ
    View PubMed
  • FRONT MED-LAUSANNE 2022 10.3389/fmed.2022.896494 Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001 Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02010 Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646 Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003 Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.4663 Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.03.034 Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER-AM CANCER SOC 2022 10.1002/cncr.34176 Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma Park, S; Oh, D; Choi, YL; Chi, SA; Kim, K; Ahn, MJ; Sun, JM
    View PubMed
  • ESMO OPEN 2022 10.1016/j.esmoop.2022.100385 Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.306 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2021 10.1016/j.jtho.2021.09.007 Lung Cancer in Korea Park, S; Choi, CM; Hwang, SS; Choi, YL; Kim, HY; Kim, YC; Kim, YT; Lee, HY; Song, SY; Ahn, MJ
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.09.037 Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691 Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531 Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • BMB REP 2021 10.5483/BMBRep.2021.54.7.045 Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer Park, S; Lee, C; Ku, BM; Kim, M; Park, WY; Kim, NKD; Ahn, MJ
    View PubMed
  • Mol Cancer Res / 2020.09.30 Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer Sehhoon Park 1, Eunjin Lee , Seri Park , Sohee Lee , Seok Jin Nam , Seok Won Kim , Jeong Eon Lee , Jong-Han Yu , Ji-Yeon Kim , Jin Seok Ahn , Young-Hyuck Im , Woong-Yang Park , Kyunghee Park , Yeon Hee Park
    View PubMed
  • Expert Opin Pharmacother / 2020.11.30 Evaluating entrectinib as a treatment option for non-small cell lung cancer Jiyun Lee 1, Sehhoon Park , Hyun Ae Jung , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Myung-Ju Ahn
    View PubMed
  • J Neurooncol / 2020.09.30 Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR Minjung Seong 1, Sehhoon Park , Sung Tae Kim , Sung Goo Park , Yi Kyung Kim , Hyung-Jin Kim , Myung-Ju Ahn
    View PubMed
  • Cancer Res Treat / 2020.10.31 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Sehhoon Park 1, Bo Mi Ku , Hyun Ae Jung , Jong-Mu Sun , Jin Seok Ahn , Se-Hoon Lee , Keunchil Park , Myung-Ju Ahn
    View PubMed
  • Cancer / 2020.09.01 Biomarker?driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum?based chemotherapy Sehhoon Park 1, Joonho Shim , Peter G S Mortimer , Simon A Smith , Robert E Godin , Simon J Hollingsworth , Hee-Jung Kim , Hyun Ae Jung , Jong-Mu Sun , Woong-Yang Park , Jin Seok Ahn , Myung-Ju Ahn , Se-Hoon Lee , Keunchil Park
    View PubMed
  • Ann Oncol / 2020.10.31 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy S Park 1, M-H Lee , M Seong , S T Kim , J-H Kang , B C Cho , K H Lee , E K Cho , J-M Sun , S-H Lee , J S Ahn , K Park , M-J Ahn
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234 Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M? Park1, S; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9100326 Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations? Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.278 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • J NEURO-ONCOL 2020 10.1007/s11060-020-03617-2 Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal added value of contrast-enhanced 2D axial T2 FLAIR Seong1, M; Park, S; Kim, ST; Park, SG; Kim, YK; Kim, HJ; Ahn, MJ
    View PubMed
  • MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108 Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
    View PubMed
  • CANCER 2020 10.1002/cncr.33048 Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 Evaluating entrectinib as a treatment option for non-small cell lung cancer Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J Thorac Oncol / 2019.12.31 In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. Sehhoon Park 1, Se-Hoon Lee , Keunchil Park
    View PubMed
  • AACR / 2019년 Clinical characteristics and combined somatic mutation using target sequencing among breast cancer patients with germline BRCA mutation Park Sehhoon1, Lee Eunjin, Park Seri, Lee Sohee, Hur Joon Young, Yoon Sang Eun, Lee Kangkook, Cho Jang Ho, Kim Ji-Yeon, Ahn Jin Seok
  • J Thorac Oncol / 2019.09.30 DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC Sehhoon Park 1, Hayoon Lee , Boram Lee , Se-Hoon Lee , Jong-Mu Sun , Woong-Yang Park , Jin Seok Ahn , Myung-Ju Ahn , Keunchil Park
    View PubMed
  • Lung Cancer / 2019.01.31 Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor Sehhoon Park 1, Joungho Han , Jong-Mu Sun
    View PubMed
  • Lung Cancer / 2018.10.31 Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial Sung Won Lim 1, Sehhoon Park , Youjin Kim , Jang Ho Cho , Song Ee Park , Hansang Lee , Hee Kyung Kim , Sung Min Kim , Jong Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Myung-Ju Ahn
    View PubMed
  • J Thorac Oncol /2018.06.05 Characteristics and outcome of ROS1-positive non?small cell lung cancer patients in routine clinical practice Sehhoon Park 1, Beung-Chul Ahn , Sung Won Lim , Jong-Mu Sun , Hye Ryun Kim , Min Hee Hong , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Yoon La Choi , Byoung Chul Cho , Myung-Ju Ahn
    View PubMed
  • PLoS One / 2018.01.31 Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor Sehhoon Park 1, Seunggyun Ha , Se-Hoon Lee , Jin Chul Paeng , Bhumsuk Keam , Tae Min Kim , Dong-Wan Kim , Dae Seog Heo
    View PubMed
  • Korean J Intern Med / 2017.04.14 KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer Sehhoon Park 1, Ji-Yeon Kim , Se-Hoon Lee , Beomseok Suh , Bhumsuk Keam , Tae Min Kim , Dong-Wan Kim , Dae Seog Heo
    View PubMed
  • Ann Oncol / 2017.04.01 Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma J-K Lee 1, S Louzada , Y An , S Y Kim , S Kim , J Youk , S Park , S H Koo , B Keam , Y K Jeon , J-L Ku , F Yang , T M Kim , Y S Ju
    View PubMed
  • BMC Cancer / 2017.05.15 Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma Yeonghun Lee 1, Sehhoon Park , Se-Hoon Lee , Hyunju Lee
    View PubMed
  • Atherosclerosis / 2016.02.28 Early repolarization is associated with significant coronary artery stenosis in asymptomatic adults Beomseok Suh 1, Sehhoon Park , Dong Wook Shin , Hongkeun Ahn , Seongcheol Cho , Seung-Pyo Lee , Eun-Ah Park , Hyejin Lee , Jin Ho Park , BeLong Cho
    View PubMed
  • Medicine (Baltimore) / 2016.01.31 Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome Sehhoon Park 1, Hwi Young Kim, Haeryoung Kim, Jin Hyun Park, Jung Ho Kim, Ki Hwan Kim, Won Kim, In Sil Choi, Yong Jin Jung, Jin-Soo Kim
    View PubMed
  • Tuberc Respir Dis (Seoul) / 2015.06.30 A case of statin-induced interstitial pneumonitis due to rosuvastatin Se Yong Kim 1, Se Jin Kim , Doran Yoon , Seung Wook Hong , Sehhoon Park , Chan-Young Ock
    View PubMed
  • Hepatology / 2015.02.13 High liver fibrosis index FIB?4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers Beomseok Suh 1, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung-Kook Yang, Su Jong Yu, Cheong-Il Shin, Jin-Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho
    View PubMed